PMV Pharmaceuticals (NASDAQ:PMVP) (NASDAQ: PMVP) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for patients with solid tumors driven by dysregulated RAS signaling. Headquartered in Cambridge, Massachusetts, PMV leverages deep expertise in structure‐based drug design to create highly selective inhibitors that address key nodes in the MAPK cell‐signaling cascade. The company’s research platform integrates chemistry, computational modeling and translational biology to accelerate the discovery and optimization of novel small molecules.
The company’s lead program is a selective SOS1 inhibitor that entered Phase 1 clinical trials in patients with advanced solid tumors harboring RAS pathway alterations. PMV’s pipeline also includes discovery‐stage candidates targeting other critical components of RAS‐mediated signaling, such as downstream RAF and ERK effectors. By focusing on genetically defined tumor populations, PMV aims to deliver precision medicines that can overcome resistance mechanisms associated with current treatment options.
Since its formation in 2017, PMV has built a robust intellectual property portfolio and forged collaborations with academic institutions and research consortia to advance its oncology pipeline. The company secured initial financing through private partnerships and a successful initial public offering, positioning it to support ongoing clinical studies and expand its research activities. While its operations are centered in the United States, PMV is actively exploring strategic partnerships to facilitate global development and commercialization of its targeted therapies.
PMV Pharmaceuticals is led by chief executive officer Stephen Hurly, Ph.D., who brings over two decades of experience in oncology drug development, and chief medical officer Amanda Goetz, M.D., whose clinical expertise guides the company’s trial designs and patient engagement strategies. Supported by a multidisciplinary leadership team, PMV remains focused on advancing its innovative pipeline toward meaningful improvements in cancer care.
